Darwin Advisors LLC Sells 1,072 Shares of Johnson & Johnson (NYSE:JNJ)

Darwin Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,800 shares of the company’s stock after selling 1,072 shares during the quarter. Darwin Advisors LLC’s holdings in Johnson & Johnson were worth $2,091,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Patron Partners LLC increased its holdings in shares of Johnson & Johnson by 12.7% during the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after acquiring an additional 747 shares in the last quarter. Tandem Investment Advisors Inc. increased its holdings in shares of Johnson & Johnson by 4.8% during the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after acquiring an additional 15,003 shares in the last quarter. Argent Advisors Inc. increased its holdings in shares of Johnson & Johnson by 6.6% during the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after acquiring an additional 1,218 shares in the last quarter. Exeter Financial LLC grew its holdings in Johnson & Johnson by 3.2% during the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock worth $4,684,000 after buying an additional 819 shares in the last quarter. Finally, Fusion Capital LLC grew its holdings in Johnson & Johnson by 7.8% during the first quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock worth $4,935,000 after buying an additional 2,019 shares in the last quarter. 68.78% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.4 %

JNJ stock opened at $171.11 on Friday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37. The stock’s fifty day simple moving average is $175.21 and its two-hundred day simple moving average is $174.55. The stock has a market cap of $449.88 billion, a P/E ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the prior year, the firm earned $2.48 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on JNJ shares. Daiwa Capital Markets started coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley upped their price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group decreased their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, Credit Suisse Group upped their price target on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.